Effect of joint administration of imipramine and amantadine on binding of [3H]7-OH-DPAT to dopamine D3 receptors in peripheral blood lymphocytes of the patients with drug-resistant unipolar depression.
Treatment of the patients suffering from therapy-resistant unipolar depression with joint administration of imipramine (twice daily, 100-150 mg/day) and amantadine (twice daily, 150 mg/day) for four to six weeks resulted in the significant increase in the binding of [3H]7-OH-DPAT to dopamine D3 receptors in the peripheral blood lymphocytes. This effect correlated well with the clinical improvement, estimated with Hamilton's Depression Rating Scale. In the light of the above data, it seems justified to postulate that joint therapy with imipramine and amantadine may be successful in the treatment-resistant unipolar depression.
Dziedzicka-Wasylewska
Marta
M
Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, PL 31-343 Kraków, Poland.
Rogóz
Zofia
Z
Solich
Joanna
J
Dudek
Dominika
D
Wróbel
Andrzej
A
Zieba
Andrzej
A
D000328:Adult; D000547:Amantadine / Q000627:therapeutic use*; D001665:Binding Sites / Q000187:drug effects; D003866:Depressive Disorder / Q000188:drug therapy / Q000378:metabolism* / Q000523:psychology; D004351:Drug Resistance / Q000502:physiology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use*; D008214:Lymphocytes / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D050637:Receptors, Dopamine D3; D013764:Tetrahydronaphthalenes / Q000378:metabolism*
C493593:DRD3 protein, human; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D013764:Tetrahydronaphthalenes; D000547:Amantadine; D007099:Imipramine; C031349:7-hydroxy-2-N,N-dipropylaminotetralin